BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day

Rhea-AI Summary

BrainsWay (NASDAQ: BWAY) announced management will hold one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, in New York. Investors or analysts should contact their Citi representative to request a meeting.

Key Figures

Conference date: February 26, 2026

1 metrics

Conference date February 26, 2026 Citi 2026 Unplugged MedTech and Life Sciences Access Day

Market Reality Check

Price: $24.12 Vol: Volume 95,990 is slightly...

normal vol

$24.12 Last Close

Volume Volume 95,990 is slightly below the 20-day average of 102,711 (relative volume 0.93x). normal

Technical Price at 24.12 is above the 200-day MA of 15.67 and about 9.43% below the 52-week high of 26.63, well above the 52-week low of 7.84.

Peers on Argus

BWAY is up 0.92% while close peers show mixed moves (e.g., STIM -3.01%, CATX +4....

1 Up

BWAY is up 0.92% while close peers show mixed moves (e.g., STIM -3.01%, CATX +4.63%, OM +1.73%, VMD -0.48%, NNOX +2.10%). Momentum scanners flagged only one related name (CVRX +3.76%), supporting a stock-specific rather than broad sector move.

Historical Context

5 past events · Latest: Feb 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Minority-stake investment	Positive	-7.5%	Announced staged minority equity investment in BrainStim Health with milestone tranches.
Feb 18	Coverage expansion	Positive	+4.3%	Evernorth Behavioral Health removed prior authorization for TMS coverage.
Feb 17	ADS ratio change	Neutral	+8.6%	Changed ADS-to-ordinary share ratio to 1-to-1, a 2-for-1 ADS split.
Jan 21	Coverage policy draft	Positive	+4.7%	Highmark draft policy expanding coverage for accelerated Deep TMS protocol.
Jan 12	FDA device approval	Positive	+4.7%	FDA PMA approval for Proliv™Rx at-home neuromodulation system for MDD.

Pattern Detected

Recent operational and coverage wins have generally seen positive price reactions, with one notable selloff following an investment announcement.

Recent Company History

Over the past months, BrainsWay reported several milestones. On Jan 12, 2026, it highlighted FDA Premarket Approval for the Proliv™Rx neuromodulation system, which saw a 4.67% gain. Payer coverage updates from Highmark and Evernorth in January and February produced reactions of 4.74% and 4.29%. A 2-for-1 ADS forward split on Mar 3, 2026 drove an 8.61% move. The minority-stake BrainStim Health investment on Feb 19, 2026 coincided with a -7.45% decline.

Market Pulse Summary

This announcement highlights upcoming one-on-one investor meetings at a MedTech and life sciences ev...

Analysis

This announcement highlights upcoming one-on-one investor meetings at a MedTech and life sciences event on February 26, 2026, adding to a busy stretch of corporate updates. Recent history featured payer coverage decisions, an ADS ratio change, an FDA device approval, and a minority investment. Investors focusing on this name often monitor how such visibility events complement reimbursement progress and product adoption milestones.

AI-generated analysis. Not financial advice.

BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that management will participate in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, in New York, NY.

Please contact your Citi representative to request a meeting at the conference.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com

Investors:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

FAQ

When will BrainsWay (BWAY) participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day?

BrainsWay management will participate on Thursday, February 26, 2026 in New York City. According to the company, management will conduct one-on-one meetings at the event to engage with investors and analysts and discuss company developments.

How can investors request a meeting with BrainsWay (BWAY) at the Citi 2026 Access Day?

Investors should contact their Citi representative to request a meeting with BrainsWay management. According to the company, meeting requests are facilitated through Citi and interested parties should coordinate directly with their Citi contact prior to the event date.

What topics will BrainsWay (BWAY) management likely cover at the Citi 2026 Unplugged event?

Management will likely discuss corporate strategy, product portfolio, and market developments with attendees. According to the company, one-on-one meetings are intended for investor engagement and may cover recent business highlights and forward-looking priorities.

Where is the Citi 2026 Unplugged MedTech and Life Sciences Access Day taking place for BrainsWay (BWAY)?

The event takes place in New York, NY on February 26, 2026. According to the company, BrainsWay management will be available for scheduled one-on-one meetings at the Citi-hosted access day in New York City.

Will BrainsWay (BWAY) provide a public presentation at the Citi 2026 Unplugged MedTech and Life Sciences Access Day?

BrainsWay announced one-on-one meetings but did not mention a public presentation. According to the company, management will participate in one-on-one sessions, and investors should contact Citi for meeting availability and format details.